Holen Sie sich die Stockscreener-App
15.04
0.46%
-0.07
Handel nachbörslich:
15.36
0.32
+2.13%
Schlusskurs vom Vortag:
$15.11
Offen:
$15.18
24-Stunden-Volumen:
739.30K
Relative Volume:
0.79
Marktkapitalisierung:
$574.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-2.9318
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
+6.29%
1M Leistung:
+9.30%
6M Leistung:
-78.51%
1J Leistung:
-69.11%
1-Tages-Spanne:
$14.93
$15.40
1-Wochen-Bereich:
$14.15
$15.40
52-Wochen-Spanne:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.04 | 574.71M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - MarketBeat
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat
ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World
D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | KROS Stock News - GuruFocus
TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa
Janus Henderson Group PLC Has $226,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being - simplywall.st
Keros Therapeutics Shares Drop; Cibotercept Development Halted, Jobs Cut - marketscreener.com
KROS Halts Development of Cibotercept in PAH After Safety Concer - GuruFocus
Keros Therapeutics Announces Corporate Restructuring - citybiz
Keros Therapeutics (KROS) Restructures Focus, Faces Modest Cost Savings | KROS Stock News - GuruFocus
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% - Benzinga
Keros stock as mid-stage trial for PAH therapy ends (KROS) - Seeking Alpha
Keros Therapeutics, Inc. Announces Corporate Restructuring - marketscreener.com
Keros Therapeutics Announces Tropos Topline Data And Corporate Restructuring - marketscreener.com
Keros Therapeutics, Inc. Announces TROPOS Topline Data - marketscreener.com
KROS Announces Workforce Reduction and Strategic Evaluation | KR - GuruFocus
KROS Announces Workforce Reduction and Strategic Evaluation | KROS Stock News - GuruFocus
Keros Therapeutics halts cibotercept development, plans workforce reduction By Investing.com - Investing.com Canada
Keros Therapeutics halts PAH drug development, cuts workforce - Investing.com
Keros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate Restructuring - Nasdaq
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - Yahoo Finance
1 Stock That Turned $1,000 Into $32 Million - The Globe and Mail
Woodline Partners LP Has $6.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
D. E. Shaw & Co. Inc. Sells 174,189 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Millennium Management LLC Raises Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros secures Glass Lewis support for director nominees By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Northern Trust Corp Buys 30,111 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros secures Glass Lewis support for director nominees - Investing.com Australia
Keros Therapeutics Urges Stockholders to Vote "FOR" Director Nominees Amid Proxy Contest with ADAR1 - Nasdaq
Leading Independent Proxy Advisory Firm Glass Lewis - GlobeNewswire
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of ... - Bluefield Daily Telegraph
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees - GlobeNewswire Inc.
Keros Therapeutics (KROS) Target Price Adjusted by BofA Analyst | KROS Stock News - GuruFocus
Twinbeech Capital LP Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
(KROS) Trading Signals - news.stocktradersdaily.com
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):